234 related articles for article (PubMed ID: 30630977)
1.
Zaliova M; Potuckova E; Hovorkova L; Musilova A; Winkowska L; Fiser K; Stuchly J; Mejstrikova E; Starkova J; Zuna J; Stary J; Trka J
Haematologica; 2019 Jul; 104(7):1407-1416. PubMed ID: 30630977
[No Abstract] [Full Text] [Related]
2. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
Clappier E; Auclerc MF; Rapion J; Bakkus M; Caye A; Khemiri A; Giroux C; Hernandez L; Kabongo E; Savola S; Leblanc T; Yakouben K; Plat G; Costa V; Ferster A; Girard S; Fenneteau O; Cayuela JM; Sigaux F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Soulier J; Cavé H
Leukemia; 2014 Jan; 28(1):70-7. PubMed ID: 24064621
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.
Zhang J; McCastlain K; Yoshihara H; Xu B; Chang Y; Churchman ML; Wu G; Li Y; Wei L; Iacobucci I; Liu Y; Qu C; Wen J; Edmonson M; Payne-Turner D; Kaufmann KB; Takayanagi SI; Wienholds E; Waanders E; Ntziachristos P; Bakogianni S; Wang J; Aifantis I; Roberts KG; Ma J; Song G; Easton J; Mulder HL; Chen X; Newman S; Ma X; Rusch M; Gupta P; Boggs K; Vadodaria B; Dalton J; Liu Y; Valentine ML; Ding L; Lu C; Fulton RS; Fulton L; Tabib Y; Ochoa K; Devidas M; Pei D; Cheng C; Yang J; Evans WE; Relling MV; Pui CH; Jeha S; Harvey RC; Chen IL; Willman CL; Marcucci G; Bloomfield CD; Kohlschmidt J; Mrózek K; Paietta E; Tallman MS; Stock W; Foster MC; Racevskis J; Rowe JM; Luger S; Kornblau SM; Shurtleff SA; Raimondi SC; Mardis ER; Wilson RK; Dick JE; Hunger SP; Loh ML; Downing JR; Mullighan CG;
Nat Genet; 2016 Dec; 48(12):1481-1489. PubMed ID: 27776115
[TBL] [Abstract][Full Text] [Related]
4. High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.
Vendramini E; Giordan M; Giarin E; Michielotto B; Fazio G; Cazzaniga G; Biondi A; Silvestri D; Valsecchi MG; Muckenthaler MU; Kulozik AE; Gattei V; Izraeli S; Basso G; Te Kronnie G
Oncotarget; 2017 Jun; 8(26):42398-42413. PubMed ID: 28415578
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
7. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
[TBL] [Abstract][Full Text] [Related]
8. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
10. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.
Lilljebjörn H; Henningsson R; Hyrenius-Wittsten A; Olsson L; Orsmark-Pietras C; von Palffy S; Askmyr M; Rissler M; Schrappe M; Cario G; Castor A; Pronk CJ; Behrendtz M; Mitelman F; Johansson B; Paulsson K; Andersson AK; Fontes M; Fioretos T
Nat Commun; 2016 Jun; 7():11790. PubMed ID: 27265895
[TBL] [Abstract][Full Text] [Related]
11. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Bakker M; Hoogkamer AQ; Boer JM; Hartman QJ; Stalpers F; Escherich G; de Haas V; de Groot-Kruseman HA; Pieters R; den Boer ML
Sci Rep; 2018 Jan; 8(1):693. PubMed ID: 29330417
[TBL] [Abstract][Full Text] [Related]
12. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort.
Berry NK; Scott RJ; Sutton R; Law T; Trahair TN; Dalla-Pozza L; Ritchie P; Barbaric D; Enjeti AK
Cancer Genet; 2020 Apr; 242():8-14. PubMed ID: 32058318
[TBL] [Abstract][Full Text] [Related]
14. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
[TBL] [Abstract][Full Text] [Related]
15. Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
Gupta SK; Bakhshi S; Kamal VK; Gupta R; Sharma P; Pushpam D; Sahoo RK; Sharma A
Leuk Res; 2021 Dec; 111():106683. PubMed ID: 34371436
[TBL] [Abstract][Full Text] [Related]
16. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
[TBL] [Abstract][Full Text] [Related]
17. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
[TBL] [Abstract][Full Text] [Related]
18. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
[TBL] [Abstract][Full Text] [Related]
19. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
[TBL] [Abstract][Full Text] [Related]
20. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
